GO:0006217 deoxycytidine catabolic process: Nucleoside Metabolism Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006217 deoxycytidine catabolic process describes the chemical reactions and pathways that break down deoxycytidine, one of the four major DNA nucleosides, into its catabolic products.
• Deoxycytidine catabolism is mechanistically linked to pyrimidine salvage, deoxyribonucleotide pool balance, and the cellular pharmacology of cytidine analogues such as gemcitabine.
• Key enzymes and regulators include deoxycytidine kinase (DCK), cytidine deaminase (CDA), RRM2, and ENO1, which influence deoxycytidine synthesis, salvage, and drug resistance.
• In pancreatic ductal adenocarcinoma, deoxycytidine pathway activity and pyrimidine synthesis contribute to gemcitabine resistance and metabolic adaptation.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of deoxycytidine catabolic genes in cancer and metabolic disease.
• Spatial multi-omics and metabolic profiling reveal that stromal and metabolic gradients shape deoxycytidine-related chemotherapy responses in pancreatic cancer.
Description
GO:0006217 deoxycytidine catabolic process is a biological process term in the Gene Ontology that defines the chemical reactions and pathways resulting in the breakdown of deoxycytidine, also known as 2-deoxyribosylcytosine, one of the four major nucleosides of DNA. This process is central to pyrimidine metabolism because it controls the availability of deoxycytidine and related deoxyribonucleotides for DNA synthesis, repair, and drug activation. Researchers study deoxycytidine catabolism to understand how cells balance nucleoside salvage and degradation, and how tumors exploit these pathways to survive chemotherapy. The term is particularly relevant to cancer pharmacology because deoxycytidine analogues such as gemcitabine require intracellular activation and are counteracted by catabolic and synthetic pathways. Recent work in pancreatic cancer shows that deoxycytidine synthesis and pyrimidine metabolism are rewired during gemcitabine resistance, with ENO1 stabilizing RRM2 to promote deoxycytidine production. Additional studies demonstrate that pyrimidine synthesis disruption and redox homeostasis modulation can alleviate gemcitabine resistance, linking deoxycytidine catabolic process to therapeutic vulnerability. Thus, GO:0006217 provides a framework for interpreting metabolic, pharmacological, and CRISPR-based studies of nucleoside breakdown in health and disease.
deoxycytidine catabolic process At A Glance
| GO ID | GO:0006217 |
|---|---|
| GO term | deoxycytidine catabolic process |
| Ontology | biological_process |
| Synonym | deoxycytidine breakdown; deoxycytidine catabolism; deoxycytidine degradation |
| Definition | The chemical reactions and pathways resulting in the breakdown of deoxycytidine, 2-deoxyribosylcytosine, one of the four major nucleosides of DNA. |
| Major function | Regulates deoxycytidine and deoxyribonucleotide pools by degrading deoxycytidine and related pyrimidine nucleosides. |
| Related pathways | Pyrimidine metabolism, nucleoside salvage, gemcitabine activation and resistance. |
| Disease relevance | Pancreatic cancer chemoresistance, metabolic adaptation, and stromal metabolic support. |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, metabolic profiling, spatial multi-omics. |
What Is GO:0006217?
The deoxycytidine catabolic process (GO:0006217) is the set of biochemical reactions and pathways that degrade deoxycytidine, a deoxyribonucleoside composed of cytosine attached to a deoxyribose sugar, into smaller metabolites. In practical terms, it covers the enzymatic steps that convert deoxycytidine and its derivatives into catabolic intermediates, thereby regulating the cellular pool of this nucleoside and its phosphorylated forms. This process is distinct from deoxycytidine salvage and synthesis, although it is functionally coupled to them through shared enzymes and metabolites.
Why Is deoxycytidine catabolic process Important in Cell Biology?
Deoxycytidine catabolic process is important because it directly influences the intracellular balance of deoxycytidine and deoxyribonucleotides, which are required for DNA replication and repair and which determine the efficacy of nucleoside analogue drugs such as gemcitabine. Dysregulation of this process can shift cells toward drug resistance, as shown in pancreatic cancer models where deoxycytidine synthesis and pyrimidine metabolism support gemcitabine resistance. Understanding GO:0006217 therefore helps researchers interpret metabolic reprogramming in tumors, design combination therapies, and build CRISPR models that test causal roles of catabolic enzymes.
• Controls deoxycytidine availability for DNA synthesis and repair.
• Modulates activation and detoxification of deoxycytidine analogues such as gemcitabine.
• Contributes to pyrimidine metabolic reprogramming in pancreatic cancer.
• Links to chemotherapy resistance through RRM2 stabilization and deoxycytidine synthesis.
• Interacts with redox homeostasis and ferroptosis evasion pathways.
• Is influenced by stromal and spatial metabolic gradients in pancreatic ductal adenocarcinoma.
• Provides targets for CRISPR knockout and point-mutation studies of nucleoside metabolism.
• Supports biomarker discovery for gemcitabine response.
• Connects nucleoside catabolism to senescence and stroma stiffness programs.
• Enables metabolic flux and multi-omics interrogation of pyrimidine pathways.
What Happens During deoxycytidine catabolic process?
Substrate recognition and deoxycytidine availability
In simple terms: The cell first makes deoxycytidine available for breakdown.
Deoxycytidine catabolic process begins with the availability of deoxycytidine, a deoxyribonucleoside that can be generated through salvage or synthesis pathways and then directed toward catabolism. In cancer cells, deoxycytidine synthesis can be enhanced by ENO1-mediated stabilization of RRM2, increasing the pool of deoxycytidine available for both DNA synthesis and catabolic processing. This step is critical because the balance between deoxycytidine synthesis, salvage, and catabolism determines cellular sensitivity to gemcitabine and other cytidine analogues.
Enzymatic deamination and phosphorolysis
In simple terms: Enzymes chemically modify and split deoxycytidine into smaller pieces.
During deoxycytidine catabolism, deoxycytidine and related pyrimidine nucleosides undergo enzymatic deamination and phosphorolytic cleavage, producing catabolic intermediates that feed into broader pyrimidine degradation pathways. Cytidine deaminase (CDA) and related enzymes are implicated in the cellular pharmacology of gemcitabine, where deamination can inactivate the drug and influence resistance. These reactions are part of the chemical breakdown defined by GO:0006217 and are coupled to pyrimidine synthesis and salvage.
Integration with pyrimidine synthesis and salvage
In simple terms: Breakdown of deoxycytidine is balanced with its production.
Deoxycytidine catabolic process is not isolated; it is integrated with pyrimidine synthesis and salvage pathways that supply deoxycytidine and deoxyribonucleotides. Disruption of pyrimidine synthesis can alleviate gemcitabine resistance, indicating that catabolic and synthetic fluxes are coordinately regulated. Spatial multi-omics in pancreatic ductal adenocarcinoma further shows that cancer-associated fibroblast subtypes provide metabolic support that can reshape pyrimidine metabolism in tumor cells.
Metabolic and redox consequences
In simple terms: Breaking down deoxycytidine affects the cell's metabolic and antioxidant state.
Catabolism of deoxycytidine intersects with redox homeostasis and ferroptosis evasion, as shown by studies in pancreatic cancer where intrinsic temperature increases drive lipid metabolism toward ferroptosis evasion and chemotherapy resistance. Nanoparticles that dual-disrupt pyrimidine synthesis and redox homeostasis can alleviate gemcitabine resistance, linking deoxycytidine pathway activity to oxidative stress responses. Chemotherapy-induced senescence also promotes stromal stiffness and antioxidant adaptation, further connecting deoxycytidine catabolic process to the tumor microenvironment.
Impact on drug activation and resistance
In simple terms: How fast deoxycytidine is broken down can change how well drugs work.
The catabolic fate of deoxycytidine influences the activation and efficacy of gemcitabine, a deoxycytidine analogue used in pancreatic cancer. ENO1-mediated deoxycytidine synthesis and RRM2 stabilization promote gemcitabine resistance, highlighting how deoxycytidine pathway flux can determine therapeutic outcome. Consequently, measuring deoxycytidine catabolic process activity is important for predicting and overcoming chemoresistance.
Key Genes Involved in GO:0006217 deoxycytidine catabolic process
The following genes and proteins are experimentally linked to deoxycytidine metabolism, pyrimidine catabolism, and gemcitabine response in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DCK | Phosphorylates deoxycytidine to activate nucleoside analogues | Determines gemcitabine activation and sensitivity |
| CDA | Deaminates cytidine and deoxycytidine analogues | Influences drug inactivation and resistance |
| RRM2 | Ribonucleotide reductase subunit for deoxyribonucleotide synthesis | Stabilized by ENO1 to promote deoxycytidine synthesis and gemcitabine resistance |
| ENO1 | Glycolytic enzyme that stabilizes RRM2 | Drives deoxycytidine synthesis and chemoresistance |
| CMPK1 | Phosphorylates pyrimidine nucleoside monophosphates | Supports pyrimidine salvage and drug activation |
| NT5C | Dephosphorylates nucleoside monophosphates | Balances nucleotide pools and catabolism |
| UCK2 | Phosphorylates uridine and cytidine analogues | Contributes to pyrimidine analogue activation |
| SLC29A1 | Nucleoside transporter | Controls cellular uptake of deoxycytidine and analogues |
| SLC28A1 | Concentrative nucleoside transporter | Modulates nucleoside availability for catabolism |
| TYMP | Thymidine phosphorylase | Pyrimidine catabolism and angiogenesis |
| DPYD | Dihydropyrimidine dehydrogenase | Pyrimidine degradation and drug toxicity |
| UPB1 | Beta-ureidopropionase | Terminal pyrimidine catabolism |
| CAD | Carbamoyl-phosphate synthetase 2 | De novo pyrimidine synthesis |
| DHODH | Dihydroorotate dehydrogenase | Pyrimidine synthesis and redox balance |
| CTPS1 | CTP synthase | Pyrimidine nucleotide synthesis |
| GLS | Glutaminase | Supports pyrimidine synthesis in cancer |
| CAF markers | Stromal metabolic support | Spatial gradients affect pyrimidine metabolism |
How Is deoxycytidine catabolic process Regulated?
Deoxycytidine catabolic process is regulated at multiple levels, including enzyme expression, metabolic flux, and microenvironmental cues. ENO1-mediated stabilization of RRM2 increases deoxycytidine synthesis, indirectly shaping catabolic balance and gemcitabine resistance. Pyrimidine synthesis and redox homeostasis are coordinately regulated, as dual disruption of these pathways alleviates gemcitabine resistance. Chemotherapy-induced senescence and stromal stiffness promote antioxidant adaptation, which can further modulate pyrimidine metabolism. Spatial multi-omics reveals that cancer-associated fibroblast subtype gradients provide metabolic support and immune remodeling in pancreatic ductal adenocarcinoma, influencing pyrimidine pathway activity. Temperature-dependent lipid metabolism also drives ferroptosis evasion and chemotherapy resistance, linking environmental stress to deoxycytidine-related metabolic regulation.
deoxycytidine catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ENO1 | Pancreatic cancer gemcitabine resistance | Knockout and overexpression in PDAC cell lines |
| RRM2 | Deoxycytidine synthesis and chemoresistance | Point mutation and knock-in models |
| CDA | Nucleoside analogue inactivation | Knockout in cancer cells treated with gemcitabine |
| DCK | Gemcitabine activation | Knockout and rescue models |
| CAF markers | Stromal metabolic support in PDAC | Spatial multi-omics and co-culture models |
Pancreatic ductal adenocarcinoma and gemcitabine resistance
Pancreatic ductal adenocarcinoma is a major disease context for deoxycytidine catabolic process because gemcitabine, a deoxycytidine analogue, is a standard therapy and resistance is common. ENO1-mediated deoxycytidine synthesis and RRM2 stabilization promote gemcitabine resistance, directly linking deoxycytidine pathway flux to treatment failure. Nanoparticles that dual-disrupt pyrimidine synthesis and redox homeostasis can alleviate gemcitabine resistance, suggesting that targeting deoxycytidine metabolism is therapeutically promising. Spatial multi-omics further defines cancer-associated fibroblast subtype gradients that drive metabolic support and immune remodeling in pancreatic ductal adenocarcinoma.
Metabolic adaptation and ferroptosis evasion
Intrinsic temperature increase drives lipid metabolism toward ferroptosis evasion and chemotherapy resistance in pancreatic cancer, connecting deoxycytidine catabolic process to broader metabolic adaptation. Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation, which can further support chemoresistance. These findings indicate that deoxycytidine catabolism is embedded in a network of redox and lipid metabolic changes that tumors exploit to survive therapy.
Nucleoside analogue pharmacology
The cellular pharmacology of gemcitabine depends on deoxycytidine metabolism, including activation by deoxycytidine kinase and inactivation by cytidine deaminase. Preclinical characteristics of gemcitabine show that deoxycytidine pathway enzymes determine drug efficacy and resistance. Therefore, deoxycytidine catabolic process is a key determinant of nucleoside analogue pharmacology in cancer treatment.
From deoxycytidine catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a catabolic enzyme alter deoxycytidine levels? | CRISPR knockout cell lines |
| Does a specific point mutation change enzyme activity? | CRISPR point mutation knock-in |
| Does overexpression of ENO1 or RRM2 drive resistance? | Overexpression cell models |
| How does deoxycytidine catabolism affect drug response? | Knockout plus gemcitabine dose-response |
| What is the role of stromal metabolic support? | Co-culture and spatial multi-omics |
| Does redox modulation interact with pyrimidine synthesis? | Dual perturbation models |
How to Study the deoxycytidine catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Deoxycytidine and pyrimidine metabolite levels | Quantify catabolic flux |
| Stable isotope tracing | Metabolic pathway activity | Determine deoxycytidine synthesis vs catabolism |
| CRISPR knockout screening | Gene essentiality and drug resistance | Identify catabolic regulators |
| CRISPR point mutation knock-in | Enzyme activity changes | Test catalytic residues |
| Overexpression models | Gain-of-function effects | Validate ENO1/RRM2 roles |
| Spatial multi-omics | Tissue-level metabolic gradients | Map stromal support |
| Gemcitabine dose-response | Drug sensitivity | Link catabolism to resistance |
| Redox assays | Oxidative stress and ferroptosis | Assess metabolic crosstalk |
Metabolic profiling and flux analysis
Metabolic profiling using mass spectrometry can quantify deoxycytidine and related pyrimidine metabolites to assess catabolic flux. Stable isotope tracing can reveal how deoxycytidine is synthesized, salvaged, or degraded in cancer cells. These methods are essential for linking GO:0006217 activity to drug resistance phenotypes.
CRISPR screening and functional genomics
CRISPR knockout screens can identify genes required for deoxycytidine catabolism and gemcitabine resistance. Point mutation and knock-in models allow precise testing of enzyme active sites and regulatory residues. Overexpression models can validate gain-of-function effects of genes such as ENO1 and RRM2.
Spatial multi-omics and microenvironment analysis
Spatial multi-omics defines cancer-associated fibroblast subtype gradients that drive metabolic support and immune remodeling in pancreatic ductal adenocarcinoma. This approach can map deoxycytidine pathway activity across tumor regions and stromal compartments. Combining spatial data with metabolic profiling provides a systems view of deoxycytidine catabolic process in tissue context.
Pharmacological and resistance assays
Gemcitabine dose-response assays in knockout or overexpression cells can test how deoxycytidine catabolic process affects drug sensitivity. Cellular pharmacology studies of gemcitabine provide a foundation for interpreting these assays. Preclinical characteristics of gemcitabine further guide experimental design.
How CRISPR Can Be Used to Study GO:0006217 deoxycytidine catabolic process
Knockout
CRISPR knockout of genes such as ENO1, RRM2, DCK, or CDA can test their causal roles in deoxycytidine catabolic process and gemcitabine resistance. Knockout cell lines provide clean backgrounds for metabolic profiling and drug-response assays. These models help distinguish between synthesis, salvage, and catabolic contributions.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid changes in enzymes like DCK or CDA to test catalytic activity and substrate specificity. Such models are valuable for dissecting the molecular mechanism of deoxycytidine catabolism. They also help validate drug-binding sites and resistance mutations.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of deoxycytidine catabolic enzymes in live cells. Tagged knock-in models can be used for proteomics and imaging to localize enzymes within metabolic compartments. These models support precise measurement of enzyme abundance and turnover.
Overexpression
Overexpression of ENO1 or RRM2 can drive deoxycytidine synthesis and gemcitabine resistance, providing gain-of-function evidence. Overexpression models are useful for testing whether increased catabolic or synthetic flux is sufficient to alter drug sensitivity. They complement knockout studies to establish causality.
How EDITGENE Supports deoxycytidine catabolic process Research
Researchers studying deoxycytidine catabolic process-related genes often need to determine whether a candidate gene is causally involved in nucleoside metabolism, drug resistance, or metabolic adaptation. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point mutation, knock-in, and overexpression studies, as well as library screening and bioinformatics support, to accelerate functional validation of deoxycytidine pathway targets.
Contact EDITGENE today to design your custom CRISPR model for deoxycytidine catabolic process research.
Frequently Asked Questions About deoxycytidine catabolic process
What is deoxycytidine catabolic process?
Deoxycytidine catabolic process (GO:0006217) is the set of biochemical reactions and pathways that break down deoxycytidine, a major DNA nucleoside, into smaller metabolites.
What genes are involved in deoxycytidine catabolic process?
Genes such as DCK, CDA, RRM2, ENO1, and pyrimidine pathway enzymes are experimentally linked to deoxycytidine metabolism and catabolism.
Why is deoxycytidine catabolic process important in cancer?
It influences deoxycytidine availability and gemcitabine sensitivity, and its dysregulation contributes to chemoresistance in pancreatic cancer.
How is deoxycytidine catabolic process studied?
Researchers use metabolic profiling, CRISPR knockout and point mutation models, overexpression, and spatial multi-omics to study this process.
What is the role of ENO1 in deoxycytidine metabolism?
ENO1 stabilizes RRM2 to promote deoxycytidine synthesis and gemcitabine resistance in pancreatic cancer.
How does gemcitabine resistance relate to deoxycytidine catabolism?
Gemcitabine is a deoxycytidine analogue, and its activation or inactivation depends on deoxycytidine pathway enzymes, so catabolic flux affects resistance.
Can CRISPR knockout help study deoxycytidine catabolic process?
Yes, CRISPR knockout of candidate genes can test their causal roles in deoxycytidine metabolism and drug response.
What diseases are linked to deoxycytidine catabolic process?
Pancreatic ductal adenocarcinoma and chemotherapy resistance are the main disease contexts in the cited literature.
What methods measure deoxycytidine catabolic flux?
LC-MS metabolomics, stable isotope tracing, and metabolic profiling are commonly used to measure deoxycytidine and pyrimidine metabolites.
How does the tumor microenvironment affect deoxycytidine metabolism?
Cancer-associated fibroblast subtype gradients provide metabolic support and can reshape pyrimidine metabolism in pancreatic cancer.
Conclusion
GO:0006217 deoxycytidine catabolic process is a biologically and clinically important term that describes how cells break down deoxycytidine, thereby regulating nucleoside pools, drug activation, and metabolic adaptation. Research in pancreatic cancer shows that deoxycytidine synthesis and catabolism are rewired during gemcitabine resistance, with ENO1, RRM2, and pyrimidine pathway enzymes playing key roles. Understanding this process requires integrated approaches including CRISPR models, metabolic profiling, and spatial multi-omics. Targeting deoxycytidine catabolic process may offer new strategies to overcome chemoresistance and improve cancer therapy.
References
- 1. Li Y et al.. 2025. ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer.. Cell Death Dis 17(1):139 PMID: 41455715
- 2. de Laat V et al.. 2024. Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer.. Nat Commun 15(1):8540 PMID: 39358362
- 3. Liu X et al.. 2026. Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma.. Nat Commun 17(1) PMID: 42471321
- 4. Kamińska E et al.. 2021. Intragenomic Decarboxylation of 5-Carboxy-2'-deoxycytidine.. Angew Chem Int Ed Engl 60(43):23207-23211 PMID: 34432359
- 5. Wang Y et al.. 2026. Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma.. Biomaterials 325:123630 PMID: 40818322
- 6. Mini E et al.. 2006. Cellular pharmacology of gemcitabine.. Ann Oncol 17 Suppl 5:v7-12 PMID: 16807468
- 7. Plunkett W et al.. 1995. Preclinical characteristics of gemcitabine.. Anticancer Drugs 6 Suppl 6:7-13 PMID: 8718419
- 8. Zhang Q et al.. 2026. Spatial multi-omics defines cancer-associated fibroblasts subtype gradients driving metabolic support and immune remodeling in pancreatic ductal adenocarcinoma.. Cancer Lett 653:218585 PMID: 42144098
